339 related articles for article (PubMed ID: 32040243)
1. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis.
Cheung CKM; Law MF; Chao DC; Wong SH; Ho R; Chao ACW; Lai JWY; Chan TYT; Tam MTK; Lau SLF; Tam THC
J Dig Dis; 2020 Mar; 21(3):160-169. PubMed ID: 32040243
[TBL] [Abstract][Full Text] [Related]
2. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.
Paul S; Dickstein A; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
Hepatology; 2017 Aug; 66(2):379-388. PubMed ID: 28128861
[TBL] [Abstract][Full Text] [Related]
3. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Clin Pharmacol; 2018 Sep; 74(9):1111-1119. PubMed ID: 29845351
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan.
Chen CY; Tien FM; Cheng A; Huang SY; Chou WC; Yao M; Tang JL; Tien HF; Sheng WH
BMC Gastroenterol; 2018 Jan; 18(1):6. PubMed ID: 29310589
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.
Paul S; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
Ann Intern Med; 2016 Jan; 164(1):30-40. PubMed ID: 26595058
[TBL] [Abstract][Full Text] [Related]
7. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G
Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466
[TBL] [Abstract][Full Text] [Related]
9. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.
Mak JWY; Law AWH; Law KWT; Ho R; Cheung CKM; Law MF
World J Gastroenterol; 2023 Sep; 29(33):4942-4961. PubMed ID: 37731995
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
Zappulo E; Nicolini LA; Di Grazia C; Dominietto A; Lamparelli T; Gualandi F; Caligiuri P; Bruzzone B; Angelucci E; Viscoli C; Mikulska M
Infection; 2019 Feb; 47(1):59-65. PubMed ID: 30232604
[TBL] [Abstract][Full Text] [Related]
11. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
12. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
[TBL] [Abstract][Full Text] [Related]
14. Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.
Li P; Zhou L; Ye S; Zhang W; Wang J; Tang X; Liu J; Xu Y; Qian W; Liang A
Front Immunol; 2021; 12():638678. PubMed ID: 34335561
[TBL] [Abstract][Full Text] [Related]
15. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
Wu YT; Li X; Liu ZL; Xu Z; Dai W; Zhang K; Wu JS; Arshad B; Wu KN; Kong LQ
PLoS One; 2017; 12(6):e0179680. PubMed ID: 28640902
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.
Jiang XW; Ye JZ; Li YT; Li LJ
World J Gastroenterol; 2018 Jul; 24(28):3181-3191. PubMed ID: 30065564
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
